Janice Drew

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · JAMA Dermatology · 2020 · 339 citations · Full text

Medicine, Dermatology, Pharmacology +17

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Alice B. Gottlieb, Andrew Blauvelt, Diamant Thaçi et al. · Journal of the American Academy of Dermatology · 2018 · 155 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Mark Lebwohl, Andrew Blauvelt, C. Paul et al. · Journal of the American Academy of Dermatology · 2018 · 131 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast et al. · Journal of the American Academy of Dermatology · 2018 · 78 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials

David M. Pariser, Adelaide A. Hebert, Janice Drew et al. · American Journal of Clinical Dermatology · 2018 · 39 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +13